Europe — EFPIA and the Layered National Regulations— EU Directive 2001/83/EC, the UK ABPI Code, Germany's HWG, France's ANSM Charte — the contour of Europe's "stack-and-bind" oversight model

01Why Europe Matters — A Third Term Between the U.S. and Japan

Europe sits "between" the American and Japanese models. The U.S. runs on federal regulation plus case law that dynamically reshapes interpretation. Japan runs on a static, multi-layer net of statute + public notices + guidelines + industry code (colloquially called the "five-layer net" once each company's internal SOPs are added). Europe carries traits of both — at the EU level it sets a common floor, each country layers national law on top, and industry self-regulation layers on top of that. The architecture, viewed at multiple scales (supranational + national + industry), echoes the layered design of Vol. 2.

※ For international comparison, this article and the series as a whole compare public norms only. Internal SOPs are an internal implementation that companies in every country maintain, and are excluded from the regulatory-structure comparison.

Europe is also where most of the world's top pharma headquarters cluster — Novartis (Swiss, EFPIA member despite non-EU status), Roche (Swiss), AstraZeneca (UK), Sanofi (France), Bayer (Germany), Merck KGaA (Germany), Novo Nordisk (Denmark). Materials approved at these headquarters then flow worldwide, and they must first pass through Europe's stacked regulatory mesh. Much of what feels "Japan-specific" turns out to have a direct correspondence with Europe's tiered structure. Recognizing this is one of the discoveries of this piece.

02The European Architecture — Three Layers

European pharmaceutical advertising regulation is built on the three layers below. All member states share this basic structure, but they differentiate at Layer 02 (national law) and Layer 03 (industry codes).

Europe is a "stack from below" architecture. The EU draws the floor; nations build above; industry builds on top of that. Each layer operates independently, yet companies must conform to all layers simultaneously. The conceptual shape is close to Japan's five-layer net — but Japan stacks within a single jurisdiction, while Europe stacks across three scales (supranational, national, industry).

03EU Directive 2001/83/EC — The Common Floor

Directive 2001/83/EC is the parent statute of European pharmaceutical law. Its advertising provisions live in Title VIII (Articles 86–100).

Where the U.S. 21 CFR 202 prescribes the structure of expression around "Fair Balance" (= the principle of stating benefits and risks in fair, comparable measure), the EU Directive (= an EU rule that member states are expected to copy into national law) governs the entire promotional activity around "SmPC consistency" and "promoting rational use." The European framework treats advertising, sample provision, sponsorship, and hospitality as one integrated regime.

04The United Kingdom — The ABPI Code and PMCPA Adjudication

The UK is internationally known for the rigor of its industry self-regulation. The center is the ABPI Code of Practice for the Pharmaceutical Industry (first edition 1958, latest 2024) and its operating body, the PMCPA (Prescription Medicines Code of Practice Authority).

Defining features:

• Pre-release certification — All HCP-directed materials must be released only after dual signature: a medical signatory inside the company plus a final signatory (legal / compliance equivalent). Signed records are kept for three years per material.
• Public adjudication of violations — Complaints to PMCPA (from competing companies, healthcare professionals, or the general public) result in public adjudication. The violating company's name, the breach, and the sanction are published on the PMCPA website.
• Three-tier sanction scale — (a) Code breach found, (b) "Brought the industry into disrepute" (more serious; a finding that the industry as a whole has been damaged), (c) Audit / Public Reprimand (most serious; independent audit and public denouncement).
• The Off-Label exception — Off-label (= a use outside the approved indication or dosing) information may be provided only in response to an unsolicited request (= an inquiry the professional raised on their own, not prompted by the company) from a healthcare professional. Operates as an exception to EU Directive Art. 87.

PMCPA's public adjudications rival U.S. OPDP Warning Letters in their impact on stock price, reputation, and internal control. The dual-signature certification system echoes Japan's internal material review in spirit, but the European twist is that it is compelled by industry code, not left to corporate discretion.

05Germany — HWG's Statute-Bound Rigor

Germany sits at the opposite pole from the UK's industry-self-regulation approach: strict statutory regulation. The center is Heilmittelwerbegesetz (HWG, Drug Advertising Act), enacted in 1965 and amended many times.

Principal HWG provisions:

• §3 — General prohibition (misleading advertising, false advertising, exaggerated claims of curative power).
• §4 — Mandatory disclosures (Pflichtangaben): product name, active ingredient, indication, side effects, contraindications, precautions, and marketing authorization holder name — these must appear in every advertisement. Omission is criminally punishable.
• §7 — Total prohibition of gifts of money or goods to HCPs and pharmacists (Wertabgabenverbot). Stricter than the EFPIA Code. Items must have research or educational value, with annual cumulative caps.
• §10 — HCP-directed advertising: prescription drugs may only be advertised to healthcare professionals, pharmacists, and academic personnel.
• §11 — Public-facing advertising: prescription-drug DTC is completely prohibited (national transposition of EU Directive Art. 88).

HWG carries criminal penalties. Serious breaches (Vorsatz / intentional) can attract up to one year of imprisonment or fines; minor breaches (Fahrlässigkeit / negligent) draw fines. This is parallel to Japan's criminal-enforcement structure under Pharmaceutical Act §§66–68, but Germany has more granular text and a richer history of actual criminal application.

06France — Pre-Clearance Under ANSM Visa PM

The French distinctive is pre-clearance (Visa de Publicité Médicale, Visa PM). France is the only major European country to operate this regime.

• Scope — Prescription-drug HCP-facing advertising and promotional materials must obtain pre-clearance from ANSM (Agence nationale de sécurité du médicament et des produits de santé) before distribution.
• Review timeline — Up to two months from receipt (in practice, 1–6 weeks). Distribution without approval triggers fines and stop-distribution orders.
• Review criteria — Based on ANSM's Charte de l'Information promotionnelle (Promotional Information Charter = the agreement setting the standards promotional materials must meet). Conformity with the Marketing Authorization, SmPC consistency, rational use, Fair Balance, citation appropriateness.
• OTC advertising — Public-facing OTC advertising also requires ANSM pre-clearance and the obtaining of a Visa GP (Visa Grand Public).

Pre-clearance does not exist in the other major systems (UK, Germany, Japan, U.S.). The historical background is a strong tradition of national intervention in pharmaceutical regulation following events like the 1950s Stalinon disaster (mass deaths from an organotin-containing drug). Japanese material review is a corporate internal procedure; France lets a state agency perform an equivalent function. A fundamental difference in regulatory philosophy.

07The EFPIA Code — Europe's Industry-Wide Floor

The center of European industry self-regulation is the EFPIA Code of Practice. EFPIA brings together pharmaceutical associations across more than 30 European countries. National industry codes take EFPIA as their floor.

Key contents (2024 edition):

• Promotional Materials — All promotional materials must conform to the Marketing Authorization, maintain Fair Balance, and remain consistent with the SmPC.
• Interaction with Healthcare Professionals (HCPs) — Modest hospitality with a scientific purpose, no non-professional companions, no gifts of money or monetary equivalents.
• Transfer of Value Disclosure (HCP / HCO) — Transfer of Value (= an economic benefit a company hands over, such as money or goods) from pharma companies to HCPs (= healthcare professionals) and HCOs (= healthcare organizations) must be disclosed each year (Disclosure Code = the rule that makes these payments public annually; introduced 2016). The European parallel to the U.S. Sunshine Act (= the U.S. law that makes company payments to doctors public).
• Patient Organizations — Funding of patient organizations operates under principles of transparency and independence.
• Sample provision — Aligned with EU Directive Art. 96 minimums; internal procedures and record-keeping required.

The hallmark of EFPIA Code is its placement of transparency at the center of industry self-regulation. Through the Disclosure Code, pharmaceutical payments to healthcare professionals and organizations are published annually on each company's website. This is the European industry-self-regulatory implementation of what the U.S. Sunshine Act achieves through statute. Japan's JPMA progress on payment disclosure draws directly on this EFPIA model.

08Europe vs. Japan — Structural Comparison Across Four Dimensions

Reading Europe's layered structure alongside Japan's five-layer net:

09The Three-Way Comparison — U.S. / Europe / Japan

Putting the U.S. (Overseas 01), Europe (this piece), and Japan side by side allows each model's individuality to stand out in three dimensions.

10Connections to Other Chapters on This Site

The European comparison connects to other parts of the site:

• Yakugai History 02 — Europe's most severe casualty count from thalidomide is the historical reason for the strictness of today's European regulation.
• The International Lens 01 — United States — Contrasted against the U.S. "4 layers + case law," Europe's 3-tier structure comes into relief.
• Ad Regulations 01 — The correspondence between Pharmaceutical Act §§66–68, HWG, and EU Directive.
• Material Review Vol. 2 — Japan's 5-layer net set alongside Europe's 3 tiers + the U.S.'s 4 layers.
• Compliance 02 — The philosophical foundation of transparency (Sunshine / Disclosure) and the architecture of social trust.